NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









ADvantage Therapeutics Inc.

ADvantage Therapeutics Inc.

Private
Miami, FloridaHealthcare & Life Scienceshttps://advantagetherapeutics.com/

Last Round

Grant

Sep 26, 2025

Total Funding Raised

$23M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

ADvantage Therapeutics Inc. is a biotechnology company that develops novel therapies for neurodegenerative conditions, with a primary focus on Alzheimer's disease.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologydrug discoveryKlotho proteinage-related diseasesclinical trialsbiotechmetabolic regulationmRNA therapeuticsneurodegenerative conditionsdrug developmenttherapeutic pipelinelongevity researchbiotech startupclinical-stage biotechsmall-molecule drugs

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

ADvantage Therapeutics Inc. Comparables

Compare ADvantage Therapeutics Inc. with similar companies based on industry and business-model similarity.

ADvantage Therapeutics Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Klothea Bio, Inc.
87%
Klotho Therapeutics, Inc.
85%
Klogene Therapeutics, Inc.
83%

ADvantage Therapeutics Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantSep 26, 2025
SeedNov 25, 2024
Early FundingJul 12, 2023
SeedJun 1, 2022

Key People

Founding team and executive leadership

Jeffrey Madden

Co-Founder And CEO

Founding Team

Thomas Hoffmann

Chief Technology Officer

Executive Team

David Buchsbaum

Chief Financial Officer

Executive Team

Olivier Jarry

Chief Operating Officer

Executive Team

ADvantage Therapeutics Inc. Investors

Notable investors and investment history

ADvantage Therapeutics Inc. investors
InvestorRounds
Longevitytech.fundSeed
National Institute on AgingGrant
quadraScope VenturesSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 20, 2026

    Monthly visitors increased 45% MoM.

  • Oct 9, 2025

    Preparing for Phase 1B trial of next-generation Klotho therapeutics.

ADvantage Therapeutics Inc. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

ADvantage Therapeutics Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about ADvantage Therapeutics Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersMiami, Florida
Employee Range13
Year Founded2021
Last FundingSep 26, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.